Health Care • Biotechnology: Pharmaceutical Preparations
$371.56 ▼ -1.80
(-0.48%)
MKT CAP: $42.25B • VOL: 268.1K
52W L $254 52W H $389
ONC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.34B | $3.81B | $2.46B |
| YoY Revenue Growth % | +40.2% | +55.0% | — |
| Gross Profit | $4.67B | $3.22B | $1.08B |
| Gross Margin % | 87.5% | 84.4% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $447.1M | -$568.2M | -$1.21B |
| Operating Margin % | 8.4% | -14.9% | -49.1% |
| Net Income (GAAP) | $286.9M | -$644.8M | -$881.7M |
| EBITDA (Normalized) | $595.8M | -$174.1M | -$1.12B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.13B | -$140.6M | -$1.16B |
| Capital Expenditures (CapEx) | $185.8M | $492.7M | $110.6M |
| Free Cash Flow (FCF) | $941.7M | -$633.3M | -$1.27B |
| FCF Margin % | 17.6% | -16.6% | -51.6% |
| Return on Invested Capital (ROIC %) | 45.5% | -45.0% | -6.8% |
| Cash & Short-Term Equivalents | $4.55B | $2.63B | $2.56B |
| Total Debt (Short + Long Term) | $961.9M | $166.5M | $5.44B |
| Total Stockholders' Equity | $4.36B | $3.33B | $11.15B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ONC.